This database contains 10 studies, archived under the term: "sertraline"
Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease
Munro, Cynthia A.,
Longmire, Crystal Flynn,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine E.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objectives: Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo.; Design: Placebo-controlled, randomized, double-blind trial.; Setting: Outpatient memory […]
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial–a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine
Banerjee, S.,
Hellier, J.,
Romeo, R.,
Dewey, M.,
Knapp, M.,
Ballard, C.,
Baldwin, R.,
Bentham, P.,
Fox, C.,
Holmes, C.,
Katona, C.,
Lawton, C.,
Lindesay, J.,
Livingston, G.,
McCrae, N.,
Moniz-Cook, E.,
Murray, J.,
Nurock, S.,
Orrell, M.,
O'Brien, J.,
Poppe, M.,
Thomas, A.,
Walwyn, R.,
Wilson, K.,
Burns, A.
Objective: Depression is common in dementia, causing considerable distress and other negative impacts. Treating it is a clinical priority, but the evidence base is sparse and equivocal. This trial aimed to determine clinical effectiveness of sertraline and mirtazapine in reducing depression 13 weeks post randomisation compared with placebo.; Design: Multicentre, parallel-group, double-blind placebo-controlled randomised controlled […]
Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer’s disease study ± 2 (DIADS-2)?
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine E.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objective: To determine if the effect of sertraline in the depression in Alzheimer’s disease study – 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria.; Methods: DIADS-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of sertraline (target dose of 100 mg/day) for the treatment of depression […]
Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes
Weintraub, Daniel,
Rosenberg, Paul B.,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine,
Mintzer, Jacobo E.,
Porsteinsson, Anton P.,
Schneider, Lon S.,
Rabins, Peter V.,
Munro, Cynthia A.,
Meinert, Curtis L.,
Lyketsos, Constantine G.
Background: Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD.; Methods: One hundred thirty-one participants (sertraline = 67, placebo […]
Sertraline for the treatment of depression in Alzheimer disease
Rosenberg, Paul B.,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine,
Mintzer, Jacobo E.,
Weintraub, Daniel,
Porsteinsson, Anton P.,
Schneider, Lon S.,
Rabins, Peter V.,
Munro, Cynthia A.,
Meinert, Curtis L.,
Lyketsos, Constantine G.
Objective: Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled “Depression in Alzheimer’s Disease-2” to assess the efficacy and tolerability of sertraline for depression in AD.; Methods: One hundred thirty-one […]
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial
Romeo, R.,
Knapp, M.,
Hellier, J.,
Dewey, M.,
Ballard, C.,
Baldwin, R.,
Bentham, P.,
Burns, A.,
Fox, C.,
Holmes, C.,
Katona, C.,
Lawton, C.,
Lindesay, J.,
Livingston, G.,
McCrae, N.,
Moniz-Cook, E.,
Murray, J.,
Nurock, S.,
O'Brien, J.,
Poppe, M.,
Thomas, A.,
Walwyn, R.,
Wilson, K.,
Banerjee, S.
Background: Depression is a common and costly comorbidity in dementia. There are very few data on the cost-effectiveness of antidepressants for depression in dementia and their effects on carer outcomes.; Aims: To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia.; Method: A pragmatic, multicentre, randomised placebo-controlled trial with a […]
Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer’s Disease Study 2
Flynn Longmire, Crystal V.,
Drye, Lea T.,
Frangakis, Constantine E.,
Martin, Barbara K.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being.; Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease […]
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
Banerjee, Sube,
Hellier, Jennifer,
Dewey, Michael,
Romeo, Renee,
Ballard, Clive,
Baldwin, Robert,
Bentham, Peter,
Fox, Chris,
Holmes, Clive,
Katona, Cornelius,
Knapp, Martin,
Lawton, Claire,
Lindesay, James,
Livingston, Gill,
McCrae, Niall,
Moniz-Cook, Esme,
Murray, Joanna,
Nurock, Shirley,
Orrell, Martin,
O'Brien, John,
Poppe, Michaela,
Thomas, Alan,
Walwyn, Rebecca,
Wilson, Kenneth,
Burns, Alistair
Background: Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.; Methods: We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidepressants […]